CYP1A2 and coffee intake and the modifying effect of sex, age, and smoking

American Journal of Clinical Nutrition

Volumn 96, Issue 1, 2012, Pages 182-187

  Rodenburg, Eline M ^a,b   Eijgelsheim, Mark ^a   Geleijnse, Johanna M ^c   Amin, Najaf ^a   Van Duijn, Cornelia M ^a   Hofman, Albert ^a,d   Uitterlinden, Andre G ^a,d   Stricker, Bruno H ^a,b,d   Visser, Loes E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate of Health Care   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d Netherlands Consortium on Healthy Aging   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; COFFEE; COHORT ANALYSIS; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; COFFEE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; SMOKING;

EID: 84863599383     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.027102     Document Type: Article

References (32)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23. (Pubitemid 24229655)
2. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, Dahl ML. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009;10:769-78.
3. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C/A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9. (Pubitemid 29161279)
4. Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, Nolte IM, kConFab Investigators, Vink JM, Rawal R, Mangino M, et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol Psychiatry 2011.
5. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, Berndt SI, Boerwinkle E, Chanock S, Chatterjee N, et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011;7:e1002033.
6. Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK, Franke B, den Heijer M, Kovacs P, Stumvoll M, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011;20:2071-7.
7. Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008;9:625-37. (Pubitemid 351803920)
8. Lane JD, Steege JF, Rupp SL, Kuhn CM. Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol 1992;43:543-6.
9. Simon T, Becquemont L, Hamon B, Nouyrigat E, Chodjania Y, Poirier JM, Funck-Brentano C, Jaillon P. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol 2001;52:601-4.
10. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
11. Backman JT, Schroder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2008;64:17-24.
12. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
13. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep 2008;60:789-97.
14. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992;2:73-7.
15. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41:605-8. (Pubitemid 26184683)
16. Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 2008;112:1169-77.
17. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005;294:97-104.
18. Ganmaa D, Willett WC, Li TY, Feskanich D, van Dam RM, Lopez-Garcia E, Hunter DJ, Holmes MD. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. Int J Cancer 2008;122:2071-6. (Pubitemid 351441198)
19. Hallström H, Melhus H, Glynn A, Lind L, Syvanen AC, Michaelsson K. Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study. Nutr Metab (Lond) 2010;7:12.
20. Hernán MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-84. (Pubitemid 35001493)
21. Farag NH, Whitsett TL, McKey BS, Wilson MF, Vincent AS, Everson-Rose SA, Lovallo WR. Caffeine and blood pressure response: sex, age, and hormonal status. J Womens Health (Larchmt) 2010;19:1171-6.
22. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I, Mos L, Zanata G, Santonastaso M. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 2009;27:1594-601.
23. Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Curr Opin Clin Nutr Metab Care 2007;10:745-51. (Pubitemid 350293776)
24. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, Kuipers EJ, Nijsten TE, Stricker BH, Tiemeier H, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011;26:657-86.
25. Klipstein-Grobusch K, den Breeijen JH, Goldbohm RA, Geleijnse JM, Hofman A, Grobbee DE, Witteman JC. Dietary assessment in the elderly: validation of a semiquantitative food frequency questionnaire. Eur J Clin Nutr 1998;52:588-96. (Pubitemid 28395698)
26. Schreiber GB, Maffeo CE, Robins M, Masters MN, Bond AP. Measurement of coffee and caffeine intake: implications for epidemiologic research. Prev Med 1988;17:280-94.
27. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol 1996;34:119-29. (Pubitemid 26057854)
28. Rodenburg EM, Visser LE, Danser AH, Hofman A, van Noord C, Witteman JC, Uitterlinden AG, Stricker BH. Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenet Genomics 2010;20:426-34.
29. SNP Annotation and Proxy Search. Version 2.2. 2008-2012. Available from: http://www.broadinstitute.org/mpg/snap/ldsearch.php (cited September 2011).
30. The NCBI database of genetic variation. Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/ (cited September 2011).
31. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 2007;86:240-4. (Pubitemid 47041616)
32. Karjalainen MJ, Neuvonen PJ, Backman JT. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol 2008;103:157-65. (Pubitemid 352019724)